FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156406451> ?p ?o ?g. }

• W3156406451 abstract "Phellodendri Chinese Cortex has long been used to treat hyperuricemia and gout. Berberine (BBR), its characteristic ingredient, has also been shown to be effective in alleviating monosodium urate crystals-triggered gout inflammation in vitro and in vivo . Dihydroberberine (DHB) is a hydrogenated derivative of BBR that showed improved in vivo efficacy on many metabolic disorders. However, its anti-hyperuricemia effect remains underexplored. In the present work, the hypouricemic and renoprotective effects of DHB on hyperuricemic mice were investigated. The hyperuricemic mice model was induced by intraperitoneal injection of potassium oxonate (PO, 300 mg/kg) combined with intragastric administration of hypoxanthine (HX, 300 mg/kg) for 7 days. Different dosages of DHB (25, 50 mg/kg), BBR (50 mg/kg) or febuxostat (Feb, 5 mg/kg) were orally given to mice 1 h after modeling. The molecular docking results showed that DHB effectively inhibited xanthine oxidase (XOD) by binding with its active site. In vitro , DHB exhibited significant XOD inhibitory activity (IC 50 value, 34.37 μM). The in vivo results showed that DHB had obvious hypouricemic and renoprotective effects in hyperuricemic mice. It could not only lower the uric acid and XOD levels in serum, but also suppress the activities of XOD and adenosine deaminase (ADA) in the liver. Furthermore, DHB noticeably down-regulated the renal mRNA and protein expression of XOD. Besides, DHB remarkably and dose-dependently ameliorated renal damage, as evidenced by considerably reducing serum creatinine and blood urea nitrogen (BUN) levels, inflammatory cytokine (TNF-α, IL-1β, IL-6 and IL-18) levels and restoring kidney histological deteriorations. Further mechanistic investigation showed that DHB distinctly down-regulated renal mRNA and protein levels of URAT1, GLUT9, NOD-like receptor 3 (NLRP3), apoptosis-associated speck-like (ASC), caspase-1 and IL-1β. Our study revealed that DHB had outstanding hypouricemic and renoprotective effects via suppressing XOD, URAT1, GLUT9 and NLRP3 inflammasome activation in the kidney." @default.
• W3156406451 created "2021-04-26" @default.
• W3156406451 creator A5004326219 @default.
• W3156406451 creator A5027379576 @default.
• W3156406451 creator A5036277303 @default.
• W3156406451 creator A5039952647 @default.
• W3156406451 creator A5044861736 @default.
• W3156406451 creator A5048620881 @default.
• W3156406451 creator A5076123883 @default.
• W3156406451 creator A5083410699 @default.
• W3156406451 creator A5084956938 @default.
• W3156406451 creator A5091572919 @default.
• W3156406451 date "2021-04-20" @default.
• W3156406451 modified "2023-10-16" @default.
• W3156406451 title "Anti-Hyperuricemic and Nephroprotective Effects of Dihydroberberine in Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice" @default.
• W3156406451 cites W1042061088 @default.
• W3156406451 cites W1506805851 @default.
• W3156406451 cites W1791161943 @default.
• W3156406451 cites W1905262090 @default.
• W3156406451 cites W1964356870 @default.
• W3156406451 cites W1967850881 @default.
• W3156406451 cites W1984782606 @default.
• W3156406451 cites W2000365724 @default.
• W3156406451 cites W2014742651 @default.
• W3156406451 cites W2018598332 @default.
• W3156406451 cites W2032563980 @default.
• W3156406451 cites W2033635014 @default.
• W3156406451 cites W2051120275 @default.
• W3156406451 cites W2059835344 @default.
• W3156406451 cites W2092953025 @default.
• W3156406451 cites W2102354025 @default.
• W3156406451 cites W2107225963 @default.
• W3156406451 cites W2120618034 @default.
• W3156406451 cites W2150602579 @default.
• W3156406451 cites W2156131531 @default.
• W3156406451 cites W2156882388 @default.
• W3156406451 cites W2318072719 @default.
• W3156406451 cites W2512331684 @default.
• W3156406451 cites W2518001215 @default.
• W3156406451 cites W2529336643 @default.
• W3156406451 cites W2555163974 @default.
• W3156406451 cites W2569078098 @default.
• W3156406451 cites W2576559149 @default.
• W3156406451 cites W2594058944 @default.
• W3156406451 cites W2767386717 @default.
• W3156406451 cites W2775184009 @default.
• W3156406451 cites W2783855033 @default.
• W3156406451 cites W2887014201 @default.
• W3156406451 cites W2893043724 @default.
• W3156406451 cites W2894960999 @default.
• W3156406451 cites W2897467548 @default.
• W3156406451 cites W2898919023 @default.
• W3156406451 cites W2901640116 @default.
• W3156406451 cites W2910951675 @default.
• W3156406451 cites W2925190816 @default.
• W3156406451 cites W2945865746 @default.
• W3156406451 cites W2951104379 @default.
• W3156406451 cites W2965418060 @default.
• W3156406451 cites W2969000266 @default.
• W3156406451 cites W3000337564 @default.
• W3156406451 cites W3010725108 @default.
• W3156406451 cites W3108917138 @default.
• W3156406451 cites W4248403572 @default.
• W3156406451 cites W7004691 @default.
• W3156406451 cites W994818366 @default.
• W3156406451 doi "https://doi.org/10.3389/fphar.2021.645879" @default.
• W3156406451 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8093860" @default.
• W3156406451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33959014" @default.
• W3156406451 hasPublicationYear "2021" @default.
• W3156406451 type Work @default.
• W3156406451 sameAs 3156406451 @default.
• W3156406451 citedByCount "23" @default.
• W3156406451 countsByYear W31564064512021 @default.
• W3156406451 countsByYear W31564064512022 @default.
• W3156406451 countsByYear W31564064512023 @default.
• W3156406451 crossrefType "journal-article" @default.
• W3156406451 hasAuthorship W3156406451A5004326219 @default.
• W3156406451 hasAuthorship W3156406451A5027379576 @default.
• W3156406451 hasAuthorship W3156406451A5036277303 @default.
• W3156406451 hasAuthorship W3156406451A5039952647 @default.
• W3156406451 hasAuthorship W3156406451A5044861736 @default.
• W3156406451 hasAuthorship W3156406451A5048620881 @default.
• W3156406451 hasAuthorship W3156406451A5076123883 @default.
• W3156406451 hasAuthorship W3156406451A5083410699 @default.
• W3156406451 hasAuthorship W3156406451A5084956938 @default.
• W3156406451 hasAuthorship W3156406451A5091572919 @default.
• W3156406451 hasBestOaLocation W31564064511 @default.
• W3156406451 hasConcept C150903083 @default.
• W3156406451 hasConcept C181199279 @default.
• W3156406451 hasConcept C185592680 @default.
• W3156406451 hasConcept C207001950 @default.
• W3156406451 hasConcept C2778102346 @default.
• W3156406451 hasConcept C2779470414 @default.
• W3156406451 hasConcept C2779721657 @default.
• W3156406451 hasConcept C2779881121 @default.
• W3156406451 hasConcept C2780402116 @default.
• W3156406451 hasConcept C2780932893 @default.
• W3156406451 hasConcept C2781116151 @default.
• W3156406451 hasConcept C55493867 @default.
• W3156406451 hasConcept C71924100 @default.

• next